Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 16, 2025 08:45 ET | Source: BioCardia, Inc.

Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction

SUNNYVALE, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
November 13, 2024 16:05 ET | Source: BioCardia, Inc.

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

SUNNYVALE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,...
July 24, 2023 07:00 ET | Source: BioCardia, Inc.

BioCardia Announces DSMB Recommendation to Pause New Enrollment in Phase III Pivotal CardiAMP Cell Therapy Heart Failure Trial While Additional Blinded Data is Collected

SUNNYVALE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease,...
June 21, 2021 08:00 ET | Source: BioCardia, Inc.

BioCardia Announces European Patent Office Decision to Grant Patent on Autologous Cell Therapy Patient Selection Diagnostic Assay

SAN CARLOS, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...
February 23, 2021 08:00 ET | Source: BioCardia, Inc.

BioCardia Signs Agreement With Leading Japanese Pharmaceutical Company for Catheter Biotherapeutic Delivery Product Candidates

SAN CARLOS, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], today announced that it has entered into an agreement with a leading Japanese pharmaceutical company related to...